argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia GravisGlobeNewsWire • 05/26/20
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/15/20
argenx reports first quarter 2020 financial results and provides business updateGlobeNewsWire • 05/14/20
Market Fairly Evaluates Argenx's Efgartigimod (ARGX-113) In Myasthenia GravisSeeking Alpha • 04/06/20
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/28/20
argenx reports full year 2019 financial results and provides fourth quarter business updateGlobeNewsWire • 02/27/20
argenx announces full exercise of underwriters’ option to purchase additional ADSsGlobeNewsWire • 11/08/19
Revisiting argenx: Leader In FcRn Space Offers Upside Potential In 2020 And BeyondSeeking Alpha • 10/18/19
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/05/19